ECSP18092481A - Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos - Google Patents

Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos

Info

Publication number
ECSP18092481A
ECSP18092481A ECSENADI201892481A ECDI201892481A ECSP18092481A EC SP18092481 A ECSP18092481 A EC SP18092481A EC SENADI201892481 A ECSENADI201892481 A EC SENADI201892481A EC DI201892481 A ECDI201892481 A EC DI201892481A EC SP18092481 A ECSP18092481 A EC SP18092481A
Authority
EC
Ecuador
Prior art keywords
ilamino
pyrazoles
pyrimidin
treatment
neurodegenerative disorders
Prior art date
Application number
ECSENADI201892481A
Other languages
English (en)
Inventor
Vicente Fidalgo Javier De
Jianwen A Feng
Joseph P Lyssikatos
Zachary K Sweeney
Anthony A Estrada
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of ECSP18092481A publication Critical patent/ECSP18092481A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

La presente revelación se refiere en general a inhibidores de LRRK2 o una de sus sales, análogos deuterados, profármacos, tautómeros, estereoisómeros farmacéuticamente aceptables o mezcla de sus estereoisómeros y sus métodos de preparación y de uso.
ECSENADI201892481A 2016-06-16 2018-12-14 Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos ECSP18092481A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662350876P 2016-06-16 2016-06-16
US201662417151P 2016-11-03 2016-11-03
US201762476581P 2017-03-24 2017-03-24
US201762510711P 2017-05-24 2017-05-24

Publications (1)

Publication Number Publication Date
ECSP18092481A true ECSP18092481A (es) 2018-12-31

Family

ID=59216078

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201892481A ECSP18092481A (es) 2016-06-16 2018-12-14 Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos

Country Status (35)

Country Link
US (6) US20170362206A1 (es)
EP (2) EP3472153B1 (es)
JP (1) JP7004459B2 (es)
KR (1) KR102553188B1 (es)
CN (2) CN109311857B (es)
AU (3) AU2017286653B2 (es)
CA (1) CA3025672A1 (es)
CL (1) CL2018003597A1 (es)
CO (1) CO2018013585A2 (es)
CR (2) CR20220182A (es)
CU (1) CU24605B1 (es)
CY (1) CY1124789T1 (es)
DO (2) DOP2018000285A (es)
EC (1) ECSP18092481A (es)
ES (1) ES2900368T3 (es)
HR (1) HRP20211923T1 (es)
HU (1) HUE056678T2 (es)
IL (3) IL299412A (es)
JO (1) JOP20180113B1 (es)
LT (1) LT3472153T (es)
MD (1) MD3472153T2 (es)
MX (3) MX2018015630A (es)
PE (2) PE20190395A1 (es)
PH (1) PH12018502427A1 (es)
PL (1) PL3472153T3 (es)
PT (1) PT3472153T (es)
RS (1) RS62868B1 (es)
SA (2) SA521430638B1 (es)
SG (2) SG11201810579YA (es)
SI (1) SI3472153T1 (es)
TN (1) TN2018000422A1 (es)
TW (1) TWI786049B (es)
UA (1) UA126231C2 (es)
WO (1) WO2017218843A1 (es)
ZA (1) ZA201900229B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
SI3472153T1 (sl) 2016-06-16 2022-01-31 Denali Therapeutics Inc. Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj
MA51222A (fr) 2017-11-21 2020-10-07 Denali Therapeutics Inc Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production
MX2020006641A (es) * 2017-12-20 2021-01-08 Denali Therapeutics Inc Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
KR20190131981A (ko) * 2018-05-18 2019-11-27 재단법인 대구경북첨단의료산업진흥재단 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
WO2020243635A1 (en) * 2019-05-31 2020-12-03 Denali Therapeutics Inc. Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment
EP3769768A1 (en) 2019-07-23 2021-01-27 Consejo Superior de Investigaciones Cientificas (CSIC) Compounds useful for the treatment of parkinson s disease
WO2021086966A1 (en) * 2019-10-29 2021-05-06 Biogen Ma Inc. Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
US20240254103A9 (en) 2020-03-23 2024-08-01 Whan In Pharmaceutical Co., Ltd. Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
EP4238975A4 (en) * 2020-10-29 2024-06-12 Suzhou Yabao Pharmaceutical R&D Co., Ltd. SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF
TW202308635A (zh) * 2021-04-30 2023-03-01 美商戴納立製藥公司 治療與監測帕金森氏病之方法
AR127470A1 (es) 2021-10-27 2024-01-31 H Lundbeck As Inhibidores de lrrk2
WO2023113510A1 (ko) 2021-12-15 2023-06-22 환인제약 주식회사 마크로사이클릭 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors
WO2024097394A1 (en) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
CN115894456A (zh) * 2022-11-13 2023-04-04 药康众拓(江苏)医药科技有限公司 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途
WO2024112746A1 (en) 2022-11-22 2024-05-30 Denali Therapeutics Inc. Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2320730A1 (en) 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
WO2003076658A2 (en) 2002-03-08 2003-09-18 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
WO2007117995A2 (en) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Kinase inhibitors
RU2009101384A (ru) 2006-06-20 2010-07-27 Новартис АГ (CH) Биомаркеры прогрессирования болезни альцгеймера
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP2010524892A (ja) 2007-04-19 2010-07-22 ノバルティス アーゲー 代謝型グルタミン酸受容体−５の修飾因子としてのニコチン酸誘導体
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
EP2164842A2 (en) 2007-05-24 2010-03-24 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2009032694A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
JP5713367B2 (ja) 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012058193A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
CA3017869C (en) * 2010-11-10 2021-07-27 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
RU2013129818A (ru) 2010-11-30 2015-01-10 Дженентек, Инк. Способы анализа и биомаркеры для гена lrrk2
WO2012174338A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Method of selecting therapeutic indications
EP2736901A1 (en) 2011-07-28 2014-06-04 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
CA2847540C (en) 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CN106349234A (zh) 2011-11-29 2017-01-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
LT2785711T (lt) 2011-11-29 2016-10-25 F.Hoffmann-La Roche Ag 2-(fenil arba pirid-3-il)aminopirimidino dariniai kaip kinazės lrrk2 moduliatoriai skirti parkinsono ligos gydymui
CA2852609C (en) 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
WO2013079496A1 (en) 2011-11-30 2013-06-06 F. Hoffmann-La Roche Ag Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2
WO2013126283A1 (en) 2012-02-20 2013-08-29 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
CA2866086C (en) 2012-03-01 2020-06-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
CN106279202A (zh) * 2012-05-03 2017-01-04 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物
CN106220615A (zh) 2012-05-03 2016-12-14 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
JP2016509602A (ja) 2013-01-25 2016-03-31 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎の処置のためのスクアリン酸誘導体
EP3010908A1 (en) 2013-02-20 2016-04-27 E. I. du Pont de Nemours and Company Fungicidal pyrazoles
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
US9676792B2 (en) 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
US20160024071A1 (en) 2013-03-15 2016-01-28 Elan Pharmaceuticals, Llc Inhibitors of lrrk2 kinase activity
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
RS57816B1 (sr) 2013-05-10 2018-12-31 Karus Therapeutics Ltd Inhibitori histon deacetilaze
AU2015210593A1 (en) 2014-01-29 2016-07-07 Glaxosmithkline Intellectual Property Development Limited Compounds
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
CA2943979A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
DK3185868T3 (da) 2014-08-25 2022-05-23 Salk Inst For Biological Studi Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
CN105461694B (zh) 2014-09-27 2019-05-24 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
EP3227297B1 (en) 2014-12-05 2021-01-20 Array Biopharma, Inc. 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
US20180042234A1 (en) 2015-03-19 2018-02-15 E I Du Pont De Nemours And Company Fungicidal pyrazoles
JP2018135268A (ja) 2015-06-05 2018-08-30 大日本住友製薬株式会社 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
EP3377629B1 (en) 2015-11-18 2023-07-05 Rosalind Franklin University of Medicine and Science Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
WO2017100703A1 (en) 2015-12-10 2017-06-15 Colin Combs Ems analogues of lyn/src-tyrosine kinase inhibitors
AU2016369584A1 (en) 2015-12-16 2018-07-19 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
SG10201913587WA (en) * 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
SI3472153T1 (sl) 2016-06-16 2022-01-31 Denali Therapeutics Inc. Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj
WO2018217946A1 (en) 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods

Also Published As

Publication number Publication date
AU2022202372A1 (en) 2022-04-28
PL3472153T3 (pl) 2022-02-07
PE20240221A1 (es) 2024-02-16
JOP20180113B1 (ar) 2022-03-14
BR112018075569A2 (pt) 2019-03-19
SA518400660B1 (ar) 2023-06-04
IL263484B1 (en) 2023-10-01
MX2018015630A (es) 2019-04-11
SI3472153T1 (sl) 2022-01-31
HRP20211923T1 (hr) 2022-03-04
CL2018003597A1 (es) 2019-02-15
CN109311857A (zh) 2019-02-05
MX2021010304A (es) 2021-10-13
IL263484A (en) 2019-01-31
CR20180592A (es) 2019-03-05
SA521430638B1 (ar) 2023-07-12
US20180208582A1 (en) 2018-07-26
US20220135546A1 (en) 2022-05-05
AU2017286653A1 (en) 2018-12-20
CY1124789T1 (el) 2022-11-25
KR20190018676A (ko) 2019-02-25
ES2900368T3 (es) 2022-03-16
TWI786049B (zh) 2022-12-11
WO2017218843A1 (en) 2017-12-21
US11834439B2 (en) 2023-12-05
DOP2018000285A (es) 2019-01-15
HUE056678T2 (hu) 2022-02-28
TW201835069A (zh) 2018-10-01
EP3472153A1 (en) 2019-04-24
EP3472153B1 (en) 2021-09-22
JOP20180113A1 (ar) 2019-01-30
CN109311857B (zh) 2021-11-12
US10590114B2 (en) 2020-03-17
IL299412A (en) 2023-02-01
CR20220182A (es) 2022-06-15
US20170362206A1 (en) 2017-12-21
US20230227436A1 (en) 2023-07-20
CN114315819A (zh) 2022-04-12
IL263484B2 (en) 2024-02-01
KR20230107407A (ko) 2023-07-14
AU2017286653B2 (en) 2021-11-04
TN2018000422A1 (en) 2020-06-15
AU2024204621A1 (en) 2024-07-18
SG10201912632YA (en) 2020-02-27
JP7004459B2 (ja) 2022-02-10
MX2022005610A (es) 2022-06-23
ZA201900229B (en) 2022-10-26
LT3472153T (lt) 2021-12-27
US11591316B2 (en) 2023-02-28
PT3472153T (pt) 2021-12-31
EP3998261A1 (en) 2022-05-18
CA3025672A1 (en) 2017-12-21
PE20190395A1 (es) 2019-03-13
UA126231C2 (uk) 2022-09-07
KR102553188B1 (ko) 2023-07-11
US11111235B2 (en) 2021-09-07
PH12018502427A1 (en) 2019-09-30
US20180051009A1 (en) 2018-02-22
SG11201810579YA (en) 2018-12-28
MD3472153T2 (ro) 2022-03-31
AU2022202372B2 (en) 2024-04-04
JP2019521984A (ja) 2019-08-08
US9932325B2 (en) 2018-04-03
DOP2023000077A (es) 2023-05-31
US20210002260A1 (en) 2021-01-07
RS62868B1 (sr) 2022-02-28
IL299415A (en) 2023-02-01
CO2018013585A2 (es) 2019-01-18
CU24605B1 (es) 2022-06-06
CU20180152A7 (es) 2019-09-04

Similar Documents

Publication Publication Date Title
ECSP18092481A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
GT201400196A (es) Compuestos de heterociclilo
AR103680A1 (es) Inhibidores selectivos de bace1
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
UY36393A (es) Síntesis de inhibidor de pi3k y sales del mismo
SV2017005474A (es) Nuevas formas sólidas de desvenlafaxina
MY195679A (en) Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders